Lista de obras -

Cardiovascular risk in rheumatoid arthritis

artículo científico publicado en 2014

Characteristics of spontaneous coagulase-negative staphylococcal spondylodiscitis: a retrospective comparative study versus Staphylococcus aureus spondylodiscitis.

artículo científico publicado en 2017

Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy

artículo científico publicado en 2015

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial

artículo científico publicado en 2014

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort

artículo científico publicado en 2016

Frequency of concomitant fibromyalgia in rheumatic diseases: Monocentric study of 691 patients

artículo científico publicado en 2017

Management of inflammatory rheumatic conditions in the elderly

scientific article published on 01 May 2019

Overview of biologic treatments in the elderly

artículo científico

Performance of Fibromyalgia Rapid Screening Tool (FiRST) to detect fibromyalgia syndrome in rheumatic diseases

artículo científico publicado en 2016

Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France

artículo científico publicado en 2016

Response to: 'Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?' by Coiffier et al

artículo científico publicado en 2019

Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.

artículo científico publicado en 2017

Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

artículo científico publicado en 2018

Rheumatoid arthritis in the elderly in the era of tight control

artículo científico publicado en 2013

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort

artículo científico publicado en 2013

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial

artículo científico publicado en 2016

The SAPHO syndrome: a single-center study of 41 adult patients

article published in 2015

The changing face of septic arthritis complicating rheumatoid arthritis in the era of biotherapies. Retrospective single-center study over 35years

artículo científico publicado en 2016

Three-decade trends in the distribution of organisms causing septic arthritis in native joints: single-center study of 374 cases

artículo científico publicado en 2014

Treatment of primary Sjögren syndrome with rituximab: a randomized trial

artículo científico publicado en 2014

Vascular effects of nonsteroidal antiinflammatory drugs

artículo científico publicado en 2013

What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica?

artículo científico publicado en 2019

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?

artículo científico publicado en 2015

Lista de obras de

Cardiovascular risk in rheumatoid arthritis

Characteristics of spontaneous coagulase-negative staphylococcal spondylodiscitis: a retrospective comparative study versus Staphylococcus aureus spondylodiscitis.

Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy

Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial

Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort

Frequency of concomitant fibromyalgia in rheumatic diseases: Monocentric study of 691 patients

Management of inflammatory rheumatic conditions in the elderly

Overview of biologic treatments in the elderly

Performance of Fibromyalgia Rapid Screening Tool (FiRST) to detect fibromyalgia syndrome in rheumatic diseases

Psoriatic arthritis treated by anti-TNFs: a monocentric trial of 102 cases in Auvergne, France

Response to: 'Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?' by Coiffier et al

Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.

Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

Rheumatoid arthritis in the elderly in the era of tight control

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort

Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial

The SAPHO syndrome: a single-center study of 41 adult patients

The changing face of septic arthritis complicating rheumatoid arthritis in the era of biotherapies. Retrospective single-center study over 35years

Three-decade trends in the distribution of organisms causing septic arthritis in native joints: single-center study of 374 cases

Treatment of primary Sjögren syndrome with rituximab: a randomized trial

Vascular effects of nonsteroidal antiinflammatory drugs

What is the starting dose of steroid prescribed by rheumatologist in the management of polymyalgia rheumatica?

Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?